Reading this on a mobile device? Try our optimized mobile version here:

December 26, 2012
Sign upForwardArchiveAdvertise
Research transforming the study of diabetes and obesity

  Top Story 
  • Researchers still seek medical treatments for obesity
    Drugs and bariatric surgery can help people lose weight but are expensive and may not do much to solve the obesity crisis in the near term, experts say. Studies continue to evaluate the efficacy of current medical interventions, but researchers also are exploring other ways to help people slim down. The Economist (12/15) LinkedInFacebookTwitterEmail this Story
  Science & Research 
  • Vision impairment increases with diabetes cases
    A study in the Journal of the American Medical Association found a 20% increase in the number of vision loss cases in the U.S. in less than a decade, coinciding with an increase in the number of people who have had diabetes for at least 10 years. While the study didn't show a causal relationship, other risk factors for nonrefractive vision loss became less prevalent over the study period. Reuters (12/12) LinkedInFacebookTwitterEmail this Story
  • Paroxetine may prevent ROS damage in diabetes patients
    The antidepressant paroxetine appeared to stave off reactive oxygen species molecules associated with hyperglycemia in diabetes patients, according to a study in Diabetes. Researchers said the drug prevents ROS damage by lowering concentrations and suppressing production of superoxide. RedOrbit (12/14) LinkedInFacebookTwitterEmail this Story
  • Diabetes drug may benefit Alzheimer's patients, study says
    An experimental drug called AC253, which was designed to treat diabetes, could block the effects of amyloid proteins that cause brain cells to die in patients with Alzheimer's disease, Canadian researchers say. The study, reported in The Journal of Neuroscience, showed that when the drug was injected into brain cells of an animal model with Alzheimer's disease, memory function was restored to near-normal levels. United Press International (12/13) LinkedInFacebookTwitterEmail this Story
  • Research ties high insulin levels to obesity in mice
    A study in Cell Metabolism found that mice with lower fasting insulin levels were less likely to become obese and showed lower inflammation rates and fat levels in the liver when exposed to a high-fat diet than mice with high insulin levels. The results suggest that obesity could be a result of high insulin levels in the body, and not the other way around, researchers said. Healthline/Healthline Blogs (12/4) LinkedInFacebookTwitterEmail this Story
  • Other News
  Products & Innovation 
  • Antibody shows weight loss, insulin benefits in study
    A newly developed antibody called mimAb1, which mimics the function of a naturally occurring molecule called fibroblast growth factor 21, helped induce weight loss and improve insulin sensitivity and BMI in obese monkeys, researchers reported in Science Translational Medicine. However, researchers said it is still unclear how the treatment would work in human patients. U.S. News & World Report/HealthDay News (11/28) LinkedInFacebookTwitterEmail this Story
  • Scoring system may predict cardiovascular death in diabetes
    Type 2 diabetes patients with the highest coronary calcium score were more than 11 times as likely to die of heart disease than those with the lowest scores, a study indicated. The results suggest coronary calcium scoring may help providers evaluate diabetes patients at risk of cardiovascular death, researchers wrote in Diabetes Care. (12/19) LinkedInFacebookTwitterEmail this Story
  • What implications will Merck's announcement that it has abandoned plans to develop a combination drug to treat T2D have on other companies' plans to develop combination drugs for diabetes patients?
    It will have no effect: Companies will still see value in combination therapies  50.00%
    It will discourage other companies from developing these therapies due to financial concerns  40.00%
    It will discourage other companies from developing these therapies due to safety/regulatory concerns  10.00%
  Trends & Technology 
  • Drugmakers connect with diabetes patients via social media
    People with diabetes, as well as diabetes drug- and device makers, have started online blogs and networks to share experiences and information about living with the disease. Some drugmakers have faced criticism for compensating or sponsoring blogs, and some critics have called for stronger FDA and Federal Trade Commission disclosure rules. Researchers at the University of California, San Diego, are studying whether social networking helps patients manage diabetes. National Public Radio (text and audio)/Shots blog (12/3) LinkedInFacebookTwitterEmail this Story
  • Successful translational R&D needs equity ownership
    Early-stage translational research and development projects in life sciences are likely to fall flat in the absence of equity ownership in startup companies, writes Atlas Venture partner Bruce Booth. Equity ownership "rewards the successful entrepreneur and binds them together with the academic founders, key advisors, and the broader shareholders," he writes. Equity rewards risk-takers and entrepreneurs, thus encouraging investment, he writes. Forbes (12/5) LinkedInFacebookTwitterEmail this Story
  • Other News
  TRI News 
  • Poll: What will be the biggest obesity-related trend in 2013?
    2012 was the year of the weight-loss drug, as the FDA approved two new treatments for obesity for the first time in 13 years. What will be the biggest obesity-related trend in 2013? Find the results of this poll in next month's TRI SmartBrief.
Major U.S. cities will follow New York City's example to ban the sale of large sodas and sugary drinks
New studies will continue to show declines in obesity rates in U.S. cities
Companies will increasingly provide incentives for employees to lose weight
Obesity will be more widely considered a national security threat
Social media tools will be widely adopted to help fight obesity
Obesity surgery rates will hit a new high

Learn more about TRI ->News & Events  |  Research Studies  |  Contact Us

How we spend our days is, of course, how we spend our lives."
--Annie Dillard,
American author

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

 Recent TRI SmartBrief Issues:   Lead Editor:   Kathryn Doherty
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.®  Legal Information